Loading stock data…
RAPP
$40.05+2.01 (+5.28%)
Market OpenUpdated 2:31 PM EDT
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rapport Therapeutics, Inc. in the Healthcare sector is trading at $40.05. The stock is currently near its 52-week high of $42.27, remaining 48.7% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why RAPP maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$40.05
Potential Upside
5%
Whystock Fair Value$42.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$54.20+35.3%
Range$40.00 – $80.00
Fundamentals
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.22%
Volume
Today's trading volume
345,705
Recent News
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
Over the last year, a good number of insiders have significantly increased their holdings in Rapport Therapeutics, Inc...
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains.
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China
In March 2026, Rapport Therapeutics granted Tenacia Biotechnology exclusive rights to develop and commercialize its clinical-stage epilepsy and bipolar candidate RAP-219 across Greater China, in a deal including a US$20 million upfront payment and up to approximately US$308 million in potential milestones plus tiered royalties. The agreement effectively turns Greater China into a major development hub for RAP-219, adding Phase 3 trial sites in China while allowing Rapport to retain rights in...